SCHEMBL2330766

SCHEMBL2330766

COC(=O)c1cc2cc(OC)ncc2n1C

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 4/20 0.41
TP53 P04637 2/20 0.40
LMNA P02545 1/20 0.40
KMT2A Q03164 2/20 0.38
NNMT P40261 1/20 0.38
MTNR1A P48039 1/20 0.38
MTNR1B P49286 1/20 0.38
PIK3CA P42336 1/20 0.36
PRKAA2 P54646 1/20 0.36
GPR35 Q9HC97 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22749095 0.85 L3MBTL1 (0.55) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL7877590 0.74 L3MBTL1 (0.72) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5426590 0.74 L3MBTL1 (1.00) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL31403543 0.73 LCK (0.51) L3MBTL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL28848963 0.72 KDM4E (0.40) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL12153737 0.72 HSD17B10 (0.47) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL19332620 0.72 L3MBTL1 (0.60) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL29715867 0.72 L3MBTL1 (0.60) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL170816 0.72 L3MBTL1 (0.60) L3MBTL1KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL3750423 0.71 GPR35 (0.58) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2534151-B1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MERCK SHARP & DOHME (NL) 2018-11-14 EP disclosed
US-8658794-B2 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof MERCK SHARP & DOHME B.V. (NL) 2014-02-25 US disclosed
EP-2534151-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MSD Oss B.V. (NL) 2012-12-19 EP disclosed
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2012-12-06 US disclosed
WO-2011095556-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS LCK, ZAP70, FYN L3MBTL1 2596/4885KDM4E 329/4885ALDH1A1 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.